A major pharmaceutical manufacturer has reached an agreement with the U.S. administration to delay the implementation of Section 232 tariffs for three years, according to an official statement released on October 10. The deal, coordinated with the Department of Commerce, is designed to support the dual goals of strengthening domestic manufacturing and lowering the cost […]
Pharmaceutical Industry Strikes Agreement to Delay Section 232 Tariffs for Three Years

